SHENZHEN, China, July 9, 2021 /PRNewswire/ — BGI is aware of reports in Reuters regarding the company’s non-invasive prenatal test (NIPT test) – NIFTY (Non-Invasive Fetal TrisomY).
BGI’s NIPT tests have been used around the world to identify genetic conditions in pregnancy. These tests provide doctors with the scientific basis to assist millions of pregnant women, leading to better health outcomes and, in some cases, saved lives.
The research that BGI has undertaken collaboratively with some of the world’s leading academic and scientific institutions has led to major medical breakthroughs that will benefit the world for many decades to come.
As a leader in life science and gene technology, BGI is committed to improving health outcomes worldwide. That is and always has been the company’s mission. Assertions that BGI is motivated by anything other than the advancement of health outcomes are both deeply disappointing and factually incorrect.
These are the facts:
BGI is a global organization driven by innovation, focused on precision medical research, and a desire to curb the harm of major diseases on humans worldwide.
Since its foundation in 1999, BGI has maintained a consistent track record of applying the strictest ethical standards and protection of data privacy and security. We established the Institute of Review Board of Bioethics and Biosafety (BGI-IRB) to recognize, advocate, and guide BGI’s life science research and technological applications.
We are proud of the achievements that our scientists have delivered, and we are committed to continuing to work with our partners around the globe to drive new advancements in life science and healthcare.